7ZA Stock Chart & Stats
€0.29
>-€0.01(-1.21%)
At close: 4:00 PM EST
€0.29
>-€0.01(-1.21%)
Day’s Range― - ―
52-Week Range€0.17 - €0.47
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€39.63M
Enterprise Value€371.41M
Total Cash (Recent Filing)€33.89M
Total Debt (Recent Filing)€689.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€8.11M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt (debt-to-equity ~0.01) materially reduces financing risk and interest burden. This structural strength preserves strategic optionality for development-stage spending, allowing management to prioritize R&D and milestone delivery without heavy fixed financing costs.
Lead Asset Targets Gadolinium AlternativeOrviglance targets a distinct clinical niche—patients unsuitable for gadolinium—creating a durable product-market fit if approved. A differentiated safety/utility profile versus standard contrast agents could translate into sustained clinical adoption and licensing or commercialization opportunities.
Burn Has Improved Versus Prior YearsA materially reduced cash burn trend versus 2022–2023 indicates better cost discipline or milestone-driven spending, improving runway prospects. Sustained lower outflows increase likelihood of funding critical trials before large additional capital raises are needed.
Bears Say
No Revenue; Persistent LossesThe company remains pre-revenue with multi-year, sizable net losses. This structural lack of commercial cash flow forces ongoing reliance on external financing, increases dilution risk, and leaves visibility to a sustainable earnings inflection dependent on successful clinical/commercial execution.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow implies continued cash consumption to fund operations and trials. This structural cash deficit constrains strategic flexibility, heightens dependence on capital markets, and risks delays or scaling back of development programs if financing tightens.
Eroding Equity And Negative ROEDeclining equity/assets and deeply negative ROE reflect balance-sheet consumption from losses. Over the medium term this reduces the company's buffer to absorb setbacks, increases probability of dilutive financing, and signals structural strain on long-term financial resilience.
Ascelia Pharma AB News
7ZA FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was €0.17 and its highest was €0.47 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is €39.63M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 47 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.012.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in DE:7ZA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―